Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review.

Qing-Qing Zhang et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 254,679 people · 2020

Randomised comparison

Lowered quality of life & behaviour

−31%−37% to −26%

Bigger than 6 in 10 on the map

As reported

HR 0.69, 95% CI 0.63–0.74

Randomised comparison

Lowered quality of life & behaviour

−29%−34% to −24%

Bigger than 6 in 10 on the map

As reported

HR 0.71, 95% CI 0.66–0.76

Range includes no effect

No clear effect on quality of life & behaviour

−1%−4% to +1%

Smaller than almost all on the map

As reported

HR 0.99, 95% CI 0.96–1.01

Not counted

Lowered quality of life & behaviour

−10%−12% to −8%

Bigger than 2 in 10 on the map

As reported

HR 0.90, 95% CI 0.88–0.92

+3 more in the walkthrough ↓

Seven numbers in the abstract

the abstract, start to end

… dysfunction in patients with T2D (HR 0.90; 95% CI [0.88, 0.92]).

… also improved cognitive dysfunction (HR 0.92; 95% CI [0.88, 0.95]).

… improvement in cognitive dysfunction (HR 0.97; 95% CI [0.87, 1.07]).

… aggravated cognitive dysfunction (HR 1.34; 95% CI [1.24, 1.43]).

… patients in the Americas and Europe (HR 0.69; 95% CI [0.63, 0.74]), (HR 0.71; 95% CI [0.66, 0.76], respectively), while metformin did not significantly improve cognitive dysfunction in Asian patients (HR 0.99; 95% CI [0.96, 1.01]).

← favours treatmentfavours comparator →

could be chance